- Alternative Therapies
- Blood, Heart and Circulation
- Bones and Muscles
- Brain and Nerves
- Child health
- Cosmetic Surgery
- Digestive System
- Disorders and Conditions
- Drugs Approvals and Trials
- Environmental Health
- Ear, Nose and Throat
- Eyes and Vision
- Female Reproductive
- Genetics and Birth Defects
- Geriatrics and Aging
- Immune System
- Kidneys and Urinary System
- Life style and Fitness
- Lungs and Breathing
- Male Reproductive
- Medical Breakthroughs
- Mental Health and Behavior
- Metabolic Problems
- Oral and Dental Health
- Pregnancy and Childbirth
- Public Health and Safety
- Sexual Health
- Skin, Hair and Nails
- Substance Abuse
- Surgery and Rehabilitation
Purdue researchers shut down a SARS cloaking system; findings could pave the way to vaccines for SARS virus, MERS
WEST LAFAYETTE, Ind. —A Purdue University-led research team has figured out how to disable a part of the SARS virus responsible for hiding it from the immune system; a critical step in developing a vaccine against the deadly disease.
Andrew Mesecar, Purdue's Walther Professor of Cancer Structural Biology, works in his lab. Mesecar leads a team of researchers working to develop treatments and vaccines for the SARS and MERS viruses. (Purdue University photo/Steven Yang)
The findings also have potential applications in the creation of vaccines against other coronaviruses, including MERS, said Andrew Mesecar, who led the research.
"This is a first step toward creating a weakened and safe virus for use in an attenuated live vaccine," said Mesecar, Purdue's Walther Professor of Cancer Structural Biology and professor of biological sciences and chemistry. "This also could serve as a molecular roadmap for performing similar studies on other coronaviruses, like MERS, because this enzyme appears to be common to all viruses within this family."
Mesecar also is a part of a research team studying and creating potential treatment compounds for the Middle East respiratory syndrome coronavirus, or MERS, that recently arrived in the United States. There is currently no treatment or vaccine for the virus, which has an estimated fatality rate of 30 percent, according to the Centers for Disease Control and Prevention.
Because MERS and SARS are related, insight into one could provide a shortcut to finding a treatment or developing a vaccine for the other.
Andrew Mesecar, Purdue's Walther Professor of Cancer Structural Biology, speaks with post-doctoral researcher Yahira M. Baez-Santos (left) in his laboratory. In the background are (from left) graduate student Sakshi Tomar and post-doctoral researcher Sarah E. St. John. Mesecar and his research team study enzymes of the SARS and MERS viruses and create molecules to treat or prevent infection. (Purdue University photo/Steven Yang)
Mesecar and his team captured the molecular structure of a key SARS enzyme, papain-like protease, and revealed how it strips a host cell of the proteins ubiquitin and ISG15, which are involved in triggering an immune response.
A paper detailing the National Institutes of Health and National Institue of Allergy and Infectious Diseases-funded work was published in PLOS Pathogens on May 22 and is available online.
"With most viruses, when a cell is infected it sends out an alarm triggering an immune response that fights the infection, but successful viruses are able to trick the immune system," Mesecar said. "By clipping off these two proteins, SARS short circuits the host cell's signaling pathways and prevents it from alerting the immune system to its presence. By removing these proteins, the enzyme serves as a biological cloaking system for the SARS virus that allows it to live and replicate undetected."
The disruption in its natural signaling pathways also causes an infected cell to miscommunicate with the cells around it, which leads to a response that eventually kills those cells, he said.
"Some treatments prevent a virus from replicating and stop further infection, but that doesn't necessarily prevent a harmful reaction to the virus," Mesecar said. "Sometimes it is the confusion in cellular communication that makes a virus lethal."
The outbreak of SARS, severe acute respiratory syndrome, in 2003 led to hundreds of deaths and thousands of illnesses, and there is currently no treatment. The virus can be transmitted through coughing or sneezing, and the infection can quickly spread from person to person, according to the CDC. SARS spread through two dozen countries over a period of a few months before it was contained. A total of 8,098 people worldwide became ill and 774 died. There have been no reported cases of SARS since 2004.
In 2012 the National Select Agent Registry Program declared SARS virus a select agent, meaning it is considered to have the potential to pose a severe threat to public health and safety.
In addition to hiding the virus from the immune system, the SARS papain-like protease, or PLpro, enzyme also is responsible for snipping the viral polyprotein into individual proteins that are essential for viral replication. While some treatments are designed to prevent viral replication, researchers working on a vaccine must retain this function, he said.
"The goal in engineering a SARS virus that could be used as a vaccine is to create one that replicates in cells but is unable to fend off the body's immune response," Mesecar said. "We want enough viral particles to be generated to properly prime the immune sytem to fight off a true infection, but without the virus being able to cause illness in the vaccinated individual."
Mesecar and his team focused on uncovering parts of the SARS PLpro enzyme that would be involved in thwarting the immune response, but which could be altered without affecting viral replication, he said.
The team used X-ray crystallography to solve the three-dimensional structure of the SARS PLpro enzyme in complex with ubiquitin. This enabled them to see how it interatced with the protein and which amino acids are involved in linking the two together. They then used computer models and simulations to determine which amino acids are likely involved in binding ISG15. The researchers mutated the amino acids identified so that the SARS PLpro enzyme could no longer interact with the host cell proteins. The team then tested the mutatant enzyme to confirm that it could still perform its role in viral replication.
In addition to Mesecar, co-authors include Purdue postdoctoral researcher Yahira M. Baez-Santos; Kiira Ratia from the University of Illinois, Chicago; and Andrew Kilianski and Susan C. Baker from the Loyola University Chicago Stritch School of Medicine.
Mesecar and his team are currently applying their findings to the MERS virus. They have shown that the MERS virus PLpro enzyme also removes ISG15 and ubiquitin from host cell proteins, and were able to crystallize the MERS Plpro enzyme in complex with ubiquitn and ISG15, he said.
Writer: Elizabeth K. Gardner, 765-494-2081, firstname.lastname@example.org
Source: Andrew Mesecar, 765-494-1924, email@example.com
Related news releases:
Note to Journalists: B-roll and sound bites of Professor Mesecar discussing his MERS research are available at ftp://news69.uns.purdue.edu/Public/MesecarMERS/
Structural basis for the ubiquitin-linkage specificity and deISGylating activity of SARS-CoV papain-like protease
Kiira Ratia, Andrew Kilianski, Yahira M. Baez-Santos, Susan C. Baker and Andrew Mesecar
Severe acute respiratory syndrome coronavirus (SARS-CoV) encodes a papain-like protease (PLpro) with both deubiquitinating (DUB) and deISGylating activities that are proposed to counteract the post-translational modification of signaling molecules that activate the innate immune response. Here we examine the structural basis for PLpro's ubiquitin chain and interferon stimulated gene 15 (ISG15) specificity. We present the X-ray crystal structure of PLpro in complex with ubiquitin-aldehyde and model the interaction of PLpro with other ubiquitin-chain and ISG15 substrates. We show that PLpro greatly prefers K48- to K63-linked ubiquitin chains, and ISG15-based substrates to those that are mono-ubiquitinated. We propose that PLpro's higher affinity for K48-linked ubiquitin chains and ISG15 stems form a bivalent mechanism of binding, where two ubiquitin-like domains prefer to bind in the palm domain of PLpro with the most distal ubiquitin domain interacting with a "ridge" region of the thumb domain. Mutagenesis of residues within this ridge region revealed that these mutants retain viral protease activity and the ability to catayze hydrolysis of mono-ubiquitin. However, a select number of thse mutatnts have a significantly reduced ability to hydrolyze the substrate ISG15-AMC, or be inhibited by K48-linked diubuiquitin. For these latter residues, we found that PLpro antagonism of the nuclear factor kappa-light-chain-enhancer of activiated B-cells (NFkB) signaling pathway is abrogated. This identification of key and unique sites in PLpro required for recognition and processing of diubiquitin and ISG15 versus mono-ubiquitin and protease activity provides new insight into ubiquitin-chain and ISG15 recognition and highlights a role for PLpro DUB and deISGYlase activity in antagonism of the innate immune response.